Efficacy of omalizumab in reducing latex allergy

Arianna Aruanno; Raffaella Chini; Eleonora Nucera

doi:10.5114/ada.2021.110072

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2021
vol. 38

Send email

Copy url:

abstract:

Letter to the Editor

Efficacy of omalizumab in reducing latex allergy

Arianna Aruanno

¹

,

Raffaella Chini

¹

,

Eleonora Nucera

¹

Allergy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Adv Dermatol Allergol 2021; XXXVIII (5): 921-923

DOI: https://doi.org/10.5114/ada.2021.110072

Online publish date: 2021/11/05

View full text Get citation

Omalizumab, a humanized monoclonal antibody that binds the CH3 domain near the binding site for the high affinity type-I IgE Fc receptors of human IgE, can neutralize free IgE and inhibit the IgE allergic pathway [1].

The current indications for treatment with omalizumab are limited to severe persistent allergic asthma and chronic spontaneous urticaria (CSU) when it is not controlled by conventional anti-H1 treatment at the maximum dosage.

In recent years, several studies [1] have shown that omalizumab is effective in a large number of IgE-mediated and non-IgE-mediated disorders, indicating that omalizumab treatment acts on many levels and not only on immunoglobulins E [2].

Efficacy of omalizumab in reducing latex allergy

Arianna Aruanno 1 , Raffaella Chini 1 , Eleonora Nucera 1

Arianna Aruanno

¹

,

Raffaella Chini

¹

,

Eleonora Nucera

¹